Acute Lymphoblastic Leukemia Market Research Report present a detailed analysis of the market listing Acute Lymphoblastic Leukemia Market size, Epidemiology, Drug therapies and pipeline for study period from 2017-2030.

Acute Lymphoblastic Leukemia Market Size, Share, Acute Lymphoblastic Leukemia Research Report, Acute Lymphoblastic Leukemia drugs, Treatment, Prevalence and Forecast

1. Key Insights
2. Executive Summary of Acute Lymphocytic Leukemia
3. SWOT Analysis of Acute Lymphocytic Leukemia
4. Acute Lymphocytic Leukemia: Market Overview at a Glance
5. Acute Lymphocytic Leukemia (ALL): Disease Background and Overview
5.1. Introduction
5.1.1. Subtypes of ALL
5.1.2. Signs and Symptoms of ALL
5.1.3. Risk Factors and Causes of ALL
5.1.4. Pathogenesis of ALL
6. Diagnosis of ALL
6.1. Blood Test
6.1.1. Complete Blood Count (CBC) and Peripheral Blood Smear
6.1.2. Blood Chemistry Tests
6.1.3. Coagulation Tests
6.2. Bone Marrow Tests
6.2.1. Bone Marrow Aspiration and Biopsy
6.3. Lab Tests used to Diagnose and Classify ALL
6.3.1. Routine Exams with a Microscope
6.3.2. Cytochemistry
6.3.3. Flow Cytometry and Immunohistochemistry
6.4. Chromosome Tests
6.4.1. Fluorescent in situ Hybridization (FISH)
6.4.2. Polymerase Chain Reaction (PCR)
6.5. Imaging Tests
6.5.1. Computerized Tomography (CT) Scan
6.5.2. Magnetic Resonance Imaging (MRI) Scan
6.6. Stages of ALL
6.6.1. B-cell ALL Staging
6.6.2. T-cell ALL Staging
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident Cases of Leukemia in the 7MM
7.3.2. Total Incident Cases of Acute Lymphoblastic Leukemia in the 7MM
7.3.3. Diagnosed cases of Acute Lymphoblastic Leukemia by Age Distribution in the 7MM
7.3.4. Subtype-specific cases of Acute Lymphoblastic Leukemia in the 7MM
7.3.5. Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in the 7MM
7.3.6. Treated cases of Acute Lymphoblastic Leukemia in the 7MM
8. The United States Epidemiology
8.1. Total Incident Cases of Acute Lymphoblastic Leukemia in the United States
8.2. Gender-specific cases of Acute Lymphoblastic Leukemia in the United States
8.3. Diagnosed cases of Acute Lymphoblastic Leukemia by Age Distribution in the United States
8.4. Subtype-specific cases of Acute Lymphoblastic Leukemia in the United States
8.5. Genetic mutation-specific cases of Acute Lymphoblastic Leukemia in the United States
8.6. Treated cases of Acute Lymphoblastic Leukemia in the United States
9. EU-5 Country-wise Epidemiology
9.1. Germany
9.1.1. Total Incident Cases of Acute Lymphoblastic Leukemia in Germany
9.1.2. Gender-specific Cases of Acute Lymphoblastic Leukemia in Germany
9.1.3. Diagnosed Cases of Acute Lymphoblastic Leukemia by Age Distribution in Germany
9.1.4. Subtype-specific Cases of Acute Lymphoblastic Leukemia in Germany
9.1.5. Genetic Mutation-specific Cases of Acute Lymphoblastic Leukemia in Germany
9.1.6. Total Treated Cases of Acute Lymphoblastic Leukemia in Germany
9.2. France
9.2.1. Total Incident Cases of Acute Lymphoblastic Leukemia in France
9.2.2. Gender-specific Cases of Acute Lymphoblastic Leukemia in France
9.2.3. Diagnosed Cases of ALL by Age Distribution in France
9.2.4. Subtype-specific Cases of Acute Lymphoblastic Leukemia in France
9.2.5. Genetic Mutation-specific Cases of Acute Lymphoblastic Leukemia in France
9.2.6. Total Treated Cases of Acute Lymphoblastic Leukemia in France
9.3. Italy
9.3.1. Total Incident Cases of Acute Lymphoblastic Leukemia in Italy
9.3.2. Gender-specific Cases of Acute Lymphoblastic Leukemia in Italy
9.3.3. Diagnosed Cases of Acute Lymphoblastic Leukemia by Age Distribution in Italy
9.3.4. Subtype-specific Cases of Acute Lymphoblastic Leukemia in Italy
9.3.5. Genetic Mutation-specific Cases of Acute Lymphoblastic Leukemia in Italy
9.3.6. Total Treated Cases of Acute Lymphoblastic Leukemia in Italy
9.4. Spain
9.4.1. Total Incident Cases of ALL in Spain
9.4.2. Gender-specific Cases of ALL in Spain
9.4.3. Diagnosed Cases of ALL by Age Distribution in Spain
9.4.4. Subtype-specific Cases of ALL in Spain
9.4.5. Genetic Mutation-specific Cases of ALL in Spain
9.4.6. Total Treated Cases of ALL in Spain
9.5. The United Kingdom
9.5.1. Total Incident Cases of ALL in the UK
9.5.2. Gender-specific Cases of ALL in the UK
9.5.3. Diagnosed Cases of ALL by Age Distribution in the UK
9.5.4. Subtype-specific Cases of ALL in the UK
9.5.5. Genetic Mutation-specific Cases of ALL in the UK
9.5.6. Total Treated Cases of ALL in the UK
10. Japan Epidemiology
10.1. Total Incident Cases of ALL in Japan
10.2. Gender-specific cases of ALL in Japan
10.3. Diagnosed cases of ALL by Age Distribution in Japan
10.4. Subtype-specific cases of ALL in Japan
10.5. Genetic mutation-specific cases of ALL in Japan
10.6. Treated cases of ALL in Japan
11. Current Treatment Practices: ALL
11.1. Chemotherapy
11.2. Targeted Therapy
11.3. Immunotherapy
11.4. Radiation Therapy
11.5. Stem Cell Transplant
12. Treatment Algorithms
13. Guideline of ALL
13.1. The National Comprehensive Cancer Network (NCCN) Guidelines for Diagnosis and Management of ALL: 2020
13.2. The European Society for Medical Oncology (ESMO)Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of ALL in Adult Patients: 2016
13.3. The Japanese Society of Hematology (JSH) Guidelines for ALL: 2017
14. Unmet Needs of Acute Lymphocytic Leukemia (ALL)
15. Patient Journey of Acute Lymphocytic Leukemia (ALL)
16. Key Endpoints in ALL Clinical Trials
17. Acute Lymphoblastic Leukemia Marketed Therapies
17.1. Key Cross
17.2. Asparlas (calaspargase pegol-mknl):Servier Pharmaceuticals
17.2.1. Product Description
17.2.2. Regulatory Milestones
17.2.3. Other Developmental Activities
17.2.4. Pivotal Clinical Trials
17.3. Blincyto (blinatumomab/MT 103):Amgen
17.3.1. Product Description
17.3.2. Regulatory Milestones
17.3.3. Other Developmental Activities
17.3.4. Pivotal Clinical Trials
17.3.5. Ongoing Current Pipeline Activity
17.4. Kymriah (tisagenlecleucel): NovartisPharmaceuticals
17.4.1. Product Description
17.4.2. Regulatory Milestones
17.4.3. Other Developmental Activities
17.4.4. Pivotal Clinical Trial
17.4.5. Ongoing Current Pipeline Activity
17.5. Besponsa (inotuzumabozogamicin): Pfizer
17.5.1. Product Description
17.5.2. Regulatory Milestones
17.5.3. Other Developmental Activities
17.5.4. Pivotal Clinical Trial
17.5.5. Ongoing Current Pipeline Activity
17.6. Erwinaze (asparaginase Erwinia chrysanthemi): Jazz Pharmaceuticals/Porton Biopharma Limited
17.6.1. Product Description
17.6.2. Regulatory Milestones
17.6.3. Other Developmental Activities
17.6.4. Pivotal Clinical Trial
17.7. Iclusig (ponatinib): Takeda (Ariad Pharmaceuticals)
17.7.1. Product Description
17.7.2. Regulatory Milestones
17.7.3. Other Developmental Activities.
17.7.4. Pivotal Clinical Trial
17.7.5. Ongoing Current Pipeline Activity
18. Emerging Therapies
18.1. Key Cross
18.2. Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)
18.2.1. Product Description
18.2.2. Other Developmental Activities
18.2.3. Clinical Development
18.3. Jakafi (ruxolitinib): Incyte Corporation/Novartis
18.3.1. Product Description
18.3.2. Other Developmental Activities
18.3.3. Clinical Development
18.4. Motixafortide (BL-8040): BioLine Rx
18.4.1. Product Description
18.4.2. Other Developmental Activities
18.4.3. Clinical Development
18.4.4. Safety and Efficacy
18.5. TC-110: TCR2 Therapeutics
18.5.1. Product Description
18.5.2. Other Developmental Activities
18.5.3. Clinical Development
18.5.4. Safety and Efficacy
18.6. Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb
18.6.1. Product Description
18.6.2. Other Developmental Activities
18.6.3. Clinical Development
18.6.4. Safety and Efficacy
18.7. TBI-1501: Takara Bio/Otsuka Pharmaceuticals
18.7.1. Product Description
18.7.2. Other Developmental Activities
18.7.3. Clinical Development
18.8. UCART19: Servier/Allogene
18.8.1. Product Description
18.8.2. Other Developmental activities
18.8.3. Clinical Development
18.8.4. Safety and Efficacy
18.9. Venetoclax: AbbVie and Roche
18.9.1. Product Description
18.9.2. Other Developmental Activities
18.9.3. Clinical Development
18.9.4. Safety and Efficacy
18.10. NiCord (omidubicel): Gamida Cell Ltd.
18.10.1. Product Description
18.10.2. Other Developmental Activities
18.10.3. Clinical Development
18.10.4. Safety and Efficacy
18.11. Eliquis (apixaban): Bristol-Myers Squibb|Pfizer
18.11.1. Product Description
18.11.2. Other Developmental Activities
18.11.3. Clinical Development
18.12. Isatuximab: Sanofi
18.12.1. Product Description
18.12.2. Other Developmental Activities
18.12.3. Clinical Development
18.13. JZP-458 (recombinant Erwinia asparaginase): Jazz Pharmaceuticals
18.13.1. Product Description
18.13.2. Other Developmental Activities
18.13.3. Clinical Development
18.14. Vyxeos (Daunorubicin and Cytarabine for Injection): Jazz Pharmaceuticals
18.14.1. Product Description
18.14.2. Clinical Development
18.14.3. Safety and Efficacy
18.15. Daratumumab: Janssen Research &amp; Development
18.15.1. Product Description
18.15.2. Other Developmental Activities
18.15.3. Clinical Development
18.16. ProTmune: Fate Therapeutics
18.16.1. Product Description
18.16.2. Other Developmental Activities
18.16.3. Clinical Development
18.16.4. Safety and Efficacy
18.17. MB-CART19.1: MiltenyiBiotec B.V. &amp; Co. KG
18.17.1. Product Description
18.17.2. Clinical Development
18.18. BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells): Bellicum Pharmaceuticals
18.18.1. Product Description
18.18.2. Clinical Development
18.18.3. Safety and Efficacy
18.19. PBCAR0191: Precision BioSciences/Servier
18.19.1. Product Description
18.19.2. Other Developmental Activities
18.19.3. Clinical Development
18.19.4. Safety and Efficacy
18.20. AUTO1: Autolus Limited
18.20.1. Product Description
18.20.2. Other Developmental Activities
18.20.3. Clinical Development
18.20.4. Safety and Efficacy
18.21. KTE-X19: Gilead Sciences
18.21.1. Product Description
18.21.2. Clinical Development
18.21.3. Safety and Efficacy
19. Conjoint Analysis of Acute Lymphocytic Leukemia (ALL)
20. Acute Lymphocytic Leukemia (ALL): Seven Major Market Analysis
20.1. Key Findings
20.2. Market Outlook: 7MM
21. 7MM Market Size
21.1. Total Market Size of Acute Lymphoblastic Leukemia in the 7MM
21.2. Total Market size of Acute Lymphoblastic Leukemia by Therapies in the 7MM
22. United States Market Size
22.1. Total Market size of Acute Lymphoblastic Leukemia in the United States
23. EU-5 Market Size
23.1. Germany Market Size
23.1.1. Total Market size of Acute Lymphoblastic Leukemia in Germany
23.2. France Market Size
23.2.1. Total Market size of Acute Lymphoblastic Leukemia in France
23.3. Italy Market Size
23.3.1. Total Market size of Acute Lymphoblastic Leukemia in Italy
23.4. Spain Market Size
23.4.1. Total Market size of Acute Lymphoblastic Leukemia in Spain
23.5. United Kingdom Market Size
23.5.1. Total Market size of Acute Lymphoblastic Leukemia in the United Kingdom
23.6. Japan Market Size
23.6.1. Total Market size of Acute Lymphoblastic Leukemia in Japan
24. Market Access and Reimbursement of Acute Lymphocytic Leukemia (ALL) Therapies
24.1. Access and Reimbursement of Advanced Therapy Medicinal Products (ATMPs) in EU-5 Countries
24.2. Access and Reimbursement of Other Therapies
25. Market Drivers of Acute Lymphocytic Leukemia (ALL)
26. Market Barriers of Acute Lymphocytic Leukemia (ALL)
27. Appendix
27.1. Bibliography
27.2. Report Methodology
28. DelveInsight Capabilities
29. Disclaimer
30. About DelveInsight

Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Acute Lymphoblastic Leukemia (ALL) - Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding..